CD274 and esophageal squamous cell carcinoma: These data suggest that, for patients with ESCC and low PD-L1 expression, it would be prudent for clinicians to emphasize the uncertainty of benefit with the addition of immunotherapy or to minimize additional toxic effects and economic burden by avoiding immunotherapy altogether.